| Literature DB >> 28813020 |
Alexandra S Silchenko1, Anatoly I Kalinovsky2, Sergey A Avilov3, Vladimir I Kalinin4, Pelageya V Andrijaschenko5, Pavel S Dmitrenok6, Ekaterina A Chingizova7, Svetlana P Ermakova8, Olesya S Malyarenko9, Tatyana N Dautova10.
Abstract
Nine new sulfated triterpene glycosides, magnumosides A₁ (1), A₂ (2), A₃ (3), A₄ (4), B₁ (5), B₂ (6), C₁ (7), C₂ (8) and C₄ (9) as well as a known colochiroside B₂ (10) have been isolated from the tropical Indo-West Pacific sea cucumber Neothynidium (=Massinium) magnum (Phyllophoridae, Dendrochirotida) collected in the Vietnamese shallow waters. The structures of new glycosides were elucidated by 2D NMR spectroscopy and mass-spectrometry. All the isolated new glycosides were characterized by the non-holostane type lanostane aglycones having 18(16)-lactone and 7(8)-double bond and differed from each other by the side chains and carbohydrate moieties structures. Magnumoside A₁ (1) has unprecedented 20(24)-epoxy-group in the aglycone side chain. Magnumosides of the group A (1-4) contained disaccharide monosulfated carbohydrate moieties, of the group B (5, 6)-tetrasaccharide monosulfated carbohydrate moieties and, finally, of the group C (7-9)-tetrasaccharide disulfated carbohydrate moieties. The cytotoxic activities of the compounds 1-9 against mouse spleen lymphocytes, the ascites form of mouse Ehrlich carcinoma cells, human colorectal carcinoma DLD-1 cells as well as their hemolytic effects have been studied. Interestingly, the erythrocytes were more sensitive to the glycosides action than spleenocytes and cancer cells tested. The compounds 3 and 7 significantly inhibited the colony formation and decreased the size of colonies of DLD-1 cancer cells at non-cytotoxic concentrations. Moreover, the synergism of effects of radioactive irradiation and compounds 3 and 7-9 at subtoxic doses on proliferation of DLD-1 cells was demonstrated.Entities:
Keywords: Neothyonidium magnum; cytotoxic activity; magnumosides; radioactive irradiation; sea cucumber; triterpene glycosides
Mesh:
Substances:
Year: 2017 PMID: 28813020 PMCID: PMC5577610 DOI: 10.3390/md15080256
Source DB: PubMed Journal: Mar Drugs ISSN: 1660-3397 Impact factor: 5.118
Figure 1Chemical structure of the glycosides 1–10 isolated from Neothyonidium magnum.
13C and 1H NMR chemical shifts of carbohydrate moieties of magnumosides of the group A (1–4), B (5, 6) and C (7–9) in C5D5N/D2O (5:1), δ in ppm, J in Hz.
| Position | 1–4, δC a | 1–4, δH b | 5, 6, δC a | 5, 6, δH b | 7–9, δC a | 7–9, δH b |
|---|---|---|---|---|---|---|
| Xyl (1→C-3) | ||||||
| 1 | 104.8 CH | 4.66 (d, 7.0) | 104.8 CH | 4.65 (d, 7.3) | 104.8 CH | 4.65 (d, 7.0) |
| 2 | 4.00 (t, 8.7) | 4.00 (t, 8.7) | 3.98 (t, 8.8) | |||
| 3 | 75.1 CH | 4.24 (t, 8.7) | 75.2 CH | 4.25 (t, 8.7) | 75.0 CH | 4.24 (t, 8.8) |
| 4 | 5.01 m | 5.04 m | 4.99 m | |||
| 5 | 63.9 CH2 | 4.77 (dd, 5.2; 11.7) | 63.9 CH2 | 4.77 (dd, 5.5; 11.9) | 63.9 CH2 | 4.76 (dd, 5.4; 11.5) |
| 3.72 (t, 11.7) | 3.71 (dd, 9.6; 11.9) | 3.71 (t, 11.8) | ||||
| Qui (1→2Xyl) | ||||||
| 1 | 105.2 CH | 5.00 (d, 7.6) | 104.7 CH | 5.00 (d, 7.8) | 104.7 CH | 4.98 (d, 7.7) |
| 2 | 76.4 CH | 3.90 (t, 9.3) | 75.8 CH | 3.88 (t, 9.1) | 75.8 CH | 3.87 (t, 8.6) |
| 3 | 76.8 CH | 4.04 (t, 9.3) | 74.7 CH | 3.97 (t, 9.1) | 74.8 CH | 3.95 (t, 9.0) |
| 4 | 3.61 (t, 8.7) | 3.51 (t, 9.1) | 3.50 (t, 9.0) | |||
| 5 | 72.8 CH | 3.66 (dd, 5.8; 8.7) | 71.3 CH | 3.65 (dd, 5.9; 9.6) | 71.4 CH | 3.63 (dd, 6.1; 9.3) |
| 6 | 18.1 CH3 | 1.53 (d, 5.9) | 17.8 CH3 | 1.61 (d, 5.9) | 17.8 CH3 | 1.60 (d, 6.1) |
| Xyl (1→4Qui) | ||||||
| 1 | 104.4 CH | 4.77 (d, 7.7) | 104.3 CH | 4.76 (d, 7.7) | ||
| 2 | 73.3 CH | 3.89 (t, 8.6) | 73.1 CH | 3.85 (t, 8.6) | ||
| 3 | 4.12 (t, 8.6) | 4.04 (t, 8.8) | ||||
| 4 | 68.7 CH | 3.94 m | 68.7 CH | 3.90 (t, 8.7) | ||
| 5 | 65.8 CH | 4.11 (dd, 5.6; 11.3) | 65.7 CH | 4.11 (dd, 5.3; 11.8) | ||
| 3.59 (t, 10.8) | 3.59 (t, 11.3) | |||||
| MeGlc (1→3Xyl) | ||||||
| 1 | 104.4 CH | 5.21 (d, 8.0) | 104.6 CH | 5.12 (d, 7.9) | ||
| 2 | 74.5 CH | 3.88 (t, 8.7) | 74.3 CH | 3.80 (t, 9.4) | ||
| 3 | 87.0 CH | 3.68 (t, 8.6) | 86.4 CH | 3.64 (t, 9.4) | ||
| 4 | 70.4 CH | 3.89 m | 69.9 CH | 3.96 (t, 9.4) | ||
| 5 | 77.5 CH | 3.90 m | 75.5 CH | 4.03 m | ||
| 6 | 61.7 CH2 | 4.38 (dd, 1.7; 11.5) | 4.97 (d, 9.4) | |||
| 4.05 (dd, 5.9; 11.5) | 4.72 (dd, 5.5; 11.0) | |||||
| OMe | 60.5 CH3 | 3.80 s | 60.5 CH3 | 3.76 s |
a Multiplicity by DEPT; b Multiplicity by 1D TOCSY; Bold—interglycosidic bond; Italic—sulfation.
1H NMR data for the aglycones of compounds 1–9 in C5D5N/D2O, δ in ppm, J in Hz.
| Position | 1 a | 2, 6, 8 b | 3 b | 4, 9 a | 5, 7 b |
|---|---|---|---|---|---|
| 1 | 1.46 m | 1.35 m | 1.34 m | 1.46 m | 1.33 m |
| 2 | 2.10 m, H | 1.94 m, H | 1.94 m, H | 2.09 m, H | 1.93 m, H |
| 1.89 m, H | 1.74 m, H | 1.73 m, H | 1.87 m, H | 1.73 m, H | |
| 3 | 3.26 (dd, 3.9, 11.6) | 3.16 (dd, 3.8, 11.5) | 3.16 (dd, 4.3, 11.7) | 3.26 (dd, 4.1, 11.8) | 3.16 (dd, 4.5, 11.4) |
| 5 | 0.98 (dd, 3.3; 11.6) | 0.86 (brd, 11.0) | 0.86 (dd, 3.9; 11.7) | 0.99 (dd, 3.6; 11.8) | 0.86 (dd, 3.3; 11.9) |
| 6 | 2.06 m, H | 1.92 m, H | 1.91 m, H | 2.05 m, H | 1.91 m, H |
| 1.96 m, H | 1.82 m, H | 1.81 m, H | 1.97 m, H | 1.81 m, H | |
| 7 | 5.61 (dt, 2.3; 7.4) | 5.57 m | 5.59 (brd, 7.4) | 5.63 (dt, 2.4; 7.3) | 5.56 (brd, 7.5) |
| 9 | 3.18 (brd, 13.7) | 3.03 (brd, 15.2) | 3.02 (brd, 14.9) | 3.23 (brd, 13.5) | 3.02 (brd, 14.7) |
| 11 | 2.03 m, H | 1.93 m | 1.94 m | 2.03 m, H | 1.95 m |
| 1.51 m, H | 1.40 m | 1.41 m | 1.54 m, H | 1.42 m | |
| 12 | 2.47 m, H | 2.50 m, H | 2.50 m | 2.62 m, H | 2.47 m, H |
| 2.03 m, H | 2.14 m, H | 2.09 m | 2.14 m, H | 2.10 m, H | |
| 15 | 2.12 (d, 13.2, H | 2.08 (d, 13.5, H | 2.10 (d, 13.5, H | 2.15 (d, 13.3, H | 2.08 (d, 13.8, H |
| 1.89 (dd, 2.6; 13.5, H | 2.01 (dd, 2.0; 13.3, H | 2.05 (brd, 11.5, H | 1.94 (dd, 2.6; 13.4, H | 2.00 (dd, 2.6; 13.4, H | |
| 16 | 4.84 br s | 5.12 br s | 5.08 br s | 5.05 (d, 1.6) | 5.14 br s |
| 17 | 2.48 s | 2.72 s | 2.69 s | 2.63 s | 2.77 s |
| 19 | 1.04 s | 0.91 s | 0.91 s | 1.05 s | 0.91 s |
| 21 | 1.32 s | 1.46 s | 1.44 s | 1.50 s | 1.47 s |
| 22 | 2.02 m | 2.05 m | 1.70 m | 1.83 m | 2.50 (br d, 6.9) |
| 1.73 m | 1.83 m | --- | 1.80 m | --- | |
| 23 | 2.08 m | 2.06 m | 1.72 m | 2.40 m | 5.92 (d, 15.8) |
| 1.87 m | 1.97 m | 1.62 m | 2.31 m | --- | |
| 24 | 3.97 (dd, 5.6; 9.3) | 4.33 (t, 6.0) | 2.00 (t, 7.4) | 5.27 (t, 7.1) | 6.13 (dt, 6.9; 8.0; 15.8) |
| 26 | 1.31 s | 5.16 br s | 4.74 br s | 1.70 s | 1.48 s |
| --- | 4.87 br s | 4.73 br s | --- | --- | |
| 27 | 1.42 s | 1.82 s | 1.65 s | 1.63 s | 1.48 s |
| 30 | 1.15 s | 0.97 s | 0.97 s | 1.15 s | 0.97 s |
| 31 | 1.31 s | 1.16 s | 1.16 s | 1.31 s | 1.16 s |
| 32 | 1.36 s | 1.37 s | 1.40 s | 1.41 s | 1.39 s |
a ratio C5D5N/D2O (4:1); b ratio C5D5N/D2O (5:1).
13C NMR data for aglycones of compounds 1–8 in C5D5N/D2O, δ in ppm, mult.
| Position | 1 a | 2, 6, 8 b | 3 b | 4, 9 a | 5, 7 b |
|---|---|---|---|---|---|
| 1 | 35.8 CH2 | 35.6 CH2 | 35.6 CH2 | 35.8 CH2 | 35.6 CH2 |
| 2 | 26.9 CH2 | 26.7 CH2 | 26.7 CH2 | 26.9 CH2 | 26.7 CH2 |
| 3 | 88.8 CH | 88.9 CH | 89.0 CH | 88.8 CH | 89.0 CH |
| 4 | 39.4 C | 39.1 C | 39.2 C | 39.4 C | 39.2 C |
| 5 | 47.7 CH | 47.5 CH | 47.6 CH | 47.6 CH | 47.5 CH |
| 6 | 23.2 CH2 | 23.1 CH2 | 23.1 CH2 | 23.2 CH2 | 23.1 CH2 |
| 7 | 122.4 CH | 122.3 CH | 122.4 CH | 122.4 CH | 122.4 CH |
| 8 | 147.6 C | 147.6 C | 147.6 C | 147.8 C | 147.6 C |
| 9 | 46.1 CH | 45.9 CH | 46.0 CH | 46.0 CH | 45.9 CH |
| 10 | 35.5 C | 35.3 C | 35.4 C | 35.5 C | 35.4 C |
| 11 | 21.8 CH2 | 21.7 CH2 | 21.7 CH2 | 21.9 CH2 | 21.7 CH2 |
| 12 | 20.1 CH2 | 20.1 CH2 | 20.2 CH2 | 20.4 CH2 | 20.1 CH2 |
| 13 | 54.9 C | 54.6 C | 54.7 C | 54.6 C | 54.7 C |
| 14 | 45.6 C | 45.9 C | 46.0 C | 45.8 C | 46.0 C |
| 15 | 44.4 CH2 | 44.2 CH2 | 44.3 CH2 | 44.5 CH2 | 44.2 CH2 |
| 16 | 79.6 CH | 80.1 CH | 80.1 CH | 79.5 CH | 80.1 CH |
| 17 | 61.6 CH | 62.2 CH | 62.3 CH | 62.2 CH | 61.4 CH |
| 18 | 180.9 C | 182.6 C | 182.8 C | 181.6 C | 182.8 C |
| 19 | 23.9 CH3 | 23.7 CH3 | 23.8 CH3 | 23.9 CH3 | 23.8 CH3 |
| 20 | 81.9 C | 71.3 C | 71.5 C | 71.1 C | 71.7 C |
| 21 | 28.0 CH3 | 26.0 CH3 | 26.0 CH3 | 26.5 CH3 | 26.4 CH3 |
| 22 | 37.7 CH2 | 38.6 CH2 | 42.0 CH2 | 42.9 CH2 | 45.8 CH2 |
| 23 | 26.8 CH2 | 29.4 CH2 | 21.7 CH2 | 22.7 CH2 | 142.8 CH |
| 24 | 86.7 CH | 75.4 CH | 38.1 CH2 | 125.1 CH | 121.9 CH |
| 25 | 70.1 C | 148.4 C | 145.9 C | 131.0 C | 69.9 C |
| 26 | 26.3 CH3 | 110.6 CH2 | 110.3 CH2 | 25.5 CH3 | 29.9 CH3 |
| 27 | 26.7 CH3 | 17.7 CH3 | 22.2 CH3 | 17.4 CH3 | 29.9 CH3 |
| 30 | 17.1 CH3 | 17.0 CH3 | 17.1 CH3 | 17.1 CH3 | 17.0 CH3 |
| 31 | 28.5 CH3 | 28.4 CH3 | 28.5 CH3 | 28.5 CH3 | 28.5 CH3 |
| 32 | 34.3 CH3 | 34.3 CH3 | 34.3 CH3 | 34.3 CH3 | 34.5 CH3 |
a ratio C5D5N/D2O (4:1); b ratio C5D5N/D2O (5:1).
Figure 21H,1H-COSY (—) and key HMBC (H→C) correlations for the aglycones of compounds 1–9.
Figure 3Key ROESY correlations for the aglycones of compounds 1–9.
Figure 4The aglycones fragmentation observed in the (−)ESI-MS/MS of compounds 1–9.
Figure 5The hypothetic scheme of the aglycones biosynthesis of glycosides of N. magnum.
Hemolytic activity of the glycosides 1–9 against mouse erythrocytes and cytotoxic activity against mouse spleenocytes and the ascites form of mouse Ehrlich carcinoma cells.
| Compound | Hemolytic Activity, ED50, μM/mL * | Cytotoxic Activity, IC50, μM/mL ** | |
|---|---|---|---|
| spleenocytes | Ehrlich carcinoma cells | ||
| 90.18 ± 1.57 | >100.00 | >100.00 | |
| 33.33 ± 0.48 | 94.18 ± 1.18 | >100.00 | |
| 12.53 ± 0.29 | 19.20 ± 0.03 | 18.95 ± 0.03 | |
| 20.12 ± 0.14 | 37.64 ± 0.00 | 28.37 ± 0.42 | |
| 49.57 ± 0.63 | >100.00 | >100.00 | |
| 58.11 ± 0.69 | >100.00 | >100.00 | |
| 6.97 ± 0.14 | 8.97 ± 0.04 | 18.65 ± 0.00 | |
| 16.20 ± 0.49 | 17.31 ± 0.43 | 37.52 ± 0.00 | |
| 6.52 ± 0.16 | 12.23 ± 0.33 | 35.06 ± 0.18 | |
| 3.15 ± 0.12 | 9.92 ± 0.12 | 35.66 ± 0.11 | |
| 0.82 ± 0.02 | 1.21 ± 0.02 | 1.39 ± 0.015 | |
* ED50 is the effective dose of compound causing 50% of hemolysis of cells; ** IC50 is a concentration of substance caused 50% reduction in cell viability.
The cytotoxic activity of the glycosides 1–9 against DLD-1 cells.
| Glycoside | IC50, µM * | Glycoside | IC50, µM * |
|---|---|---|---|
| magnumoside A1 ( | >100 | magnumoside B2 ( | >100 |
| magnumoside A2 ( | >100 | magnumoside C1 ( | 32.9 |
| magnumoside A3 ( | 30.3 | magnumoside C2 ( | 37.1 |
| magnumoside A4 ( | >100 | magnumoside C4 ( | 33.9 |
| magnumoside B1 ( | >100 | – | – |
* IC50 is a concentration of substance caused 50% reduction in cell viability.
Figure 6The effect of the glycosides 3, 7–9 on colony formation of DLD-1 cells. (A) The compounds decreased the number of colonies of cancer cells. (B) The compounds decreased the size of colonies of cancer cells. Data are shown as means ± standard deviation and the asterisks (* p < 0.05) indicates a significant decrease in colony formation of cells treated with the compounds compared with the control.
Figure 7The effect of radioactive irradiation and a combination of radioactive irradiation and the compounds 3, 7–9 on DLD-1 cancer cell proliferation. DLD-1 cells (8.0 × 103) were treated with radiation 4 Gy and the compounds 3, 7–9 (2 µM) for 96 h. Cell viability was estimated using the MTS assay. Data are represented as the mean ± SD as determined from triplicate experiments. A Student’s t-test was used to evaluate the data with the following significance levels: * p < 0.05, ** p < 0.01.